Effect of teniposide (VM-26) on the cell survival, micronuclei-induction and lactate dehydrogenase activity on V79 cells

Toxicology

Volumn 138, Issue 1, 1999, Pages 29-41

  Adiga, Satish Kumar ^a   Jagetia, Ganesh Chandra ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Cell proliferation; Cell survival; Growth kinetics; Lactate dehydrogenase release; Micronuclei; Teniposide; V79 cells

Indexed keywords

LACTATE DEHYDROGENASE; TENIPOSIDE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL STRAIN V 79; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; GENOTOXICITY; IN VITRO STUDY; MICRONUCLEUS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; CELL LINE; CELL SURVIVAL; CLONE CELLS; COLONY-FORMING UNITS ASSAY; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; L-LACTATE DEHYDROGENASE; LUNG; MICRONUCLEI, CHROMOSOME-DEFECTIVE; TENIPOSIDE;

EID: 0032877726     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(99)00075-X     Document Type: Article

References (50)

1. Anderson R.D., Berger N.A. International Commission for Protection Against Environmental Mutagens and Carcinogens Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat. Res. 309:1994;109-142.
2. Backer L.C., Allen J.W., Harrington-Brock K. et al. Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in. vivo and in vitro. Mutagenesis. 5:1990;541-547.
3. Binaschi M., Capranico G., Dal-Bo-L, Zunino F. Relationship between lethal effects and topoisomerase II mediated double-strand breaks produced by anthracyclines with different sequence specificity. Mol. Pharm. 51:1997;1053-1059.
4. Brown P.O., Cozzarelli N.R. A sign inversion mechanism of enzymatic supercoiling of DNA. Science. 206:1979;1081-1083.
5. Bruno S., Lassota P., Giaretti W., Darzynkiewicz Z. Apoptosis of rat thymocytes triggered by prednisolone camptothecin, or teniposide is selective to G0 cells and is prevented by inhibitors of proteases. Oncol. Res. 4:1992;29-35.
6. Buhl S.N., Jackson K.Y., Lubinski R., Vanderlinde R.E. Optimal conditions for assaying human lactate dehydrogenase by the lactate-to-pyruvate reaction: Arrhenium relationships for lactate dehydrogenase isoenzymes 1 and 5. Clin. Chem. 23:1977;1289-1295.
7. Bush C., McMillan T.J. Micronucleus formation in human tumor cells: lack of correlation with radiosensitvity. Br. J. Cancer. 67:1993;102-106.
8. Countryman P.I., Heddle J.A. The production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes. Mutat. Res. 41:1979;321-332.
9. Decker T., Lohmann-Matthes M.L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods. 115:1988;61-69.
10. Del Bino G., Skierski J.S., Darzynkiewicz Z. The concentration dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells. Exp. Cell Res. 195:1991;484-491.
11. DeMarini D.M., Lawrence B.K. Prophage induction by DNA topoisomerase II poisons and reactive-oxygen species: role of DNA breaks. Mutat. Res. 267:1992;1-17.
12. +/--372C mouse lymphoma cells. Mutat. Res. 187:1987;141-149.
13. Dillehay L.E., Denstman S.C., Williams J.R. Cell cycle dependence of sister chromatid exchange induction by DNA topoisomerase II inhibitors in Chinese hamster V79 cells. Cancer Res. 47:1987;206-209.
14. Fariss M.W., Brown M.K., Schmitz J.A., Reed D.J. Mechanism of chemical-induced toxicity I: use of a rapid centrifugation technique for the separation of viable and nonviable hepatocytes. Toxicol. Appl. Pharmacol. 79:1985;283-295.
15. Fenech M., Morley A.A. Measurement of micronuclei in lymphocytes Mutat Res, 147, 29-36. Mutat. Res. 147:1985;29-36.
16. Geard C.R., Chen C.Y. Micronuclei and clonogenicity following low-and high-dose-rate gamma irradiation of normal human fibroblasts. Radiat. Res. 124:1990;S56-61.
17. Glisson B.S., Ross W.E. DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol. Ther. 32:1987;89-106.
18. Gupta R.S., Bromke A., Bryant D.W., Gupta R., Singh B., McCalla D.R. Etoposide (VP 16) and teniposide (VM-26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems. Environ. Mutagen. 9:1987;43. Abstract.
19. Hansen H.H., Rorth M. Lung cancer. Cancer Chemother. Biol. Response Modif. 17:1997;444-463.
20. Holm B., Sehested M., Jensen P.B. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal dosesof etoposide and teniposide. Clin. Cancer Res. 4:1998;1367-1373.
21. Holm C., Goto T., Wang J.C., Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell. 41:1985;553-563.
22. Holm C., Covey J.M., Kerrigan D., Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 49:1989;6365-6368.
23. Jagetia G.C., Adiga S.K. Influence of various concentrations of taxol on cell survival, micronuclei induction, and LDH activity in cultured V79 cells. Cancer Lett. 96:1995;195-200.
24. Jagetia G.C., Adiga S.K. Influence of vindesine exposure on the micronucleus formation and cell survival in V79 cells. Mutat. Res. 421:1998;55-63.
25. Jagetia G.C., Vijayashree N. Micronuclei-induction and its correlation to cell survival in HeLa cells treated with different doses of adriamycin. Cancer Lett. 110:1996;123-128.
26. Kaufmann S.H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 49:1989;5870-5878.
27. 60Co gamma radiation. Radiat. Res. 115:1988;334-346.
28. Kobayashi K., Ratain M.J. New perspective on the toxicity of etoposide. Semin. Oncol. 19(Suppl 13):1992;78-83.
29. Lähdetie J., Keiski A., Suutari A., Toppari J. Etoposide (VP-16) is a potent inducer of Micronuclei in male rat meiosis: spermatid micronucleus test and DNA flow cytometry after etoposide treatment. Environ. Mol. Mutagen. 24:1994;192-202.
30. Liu L.F., Liu C.-C., Alberts B.M. Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell. 19:1980;697-707.
31. Mariya Y., Streffer C., Fuhrman C., Wojcik A. Correlation of radiation-induced micronucleus frequency with clonogenic survival in cells of one diploid and two tetraploid murine tumor cell lines of the same origin. Radiat. Res. 147:1997;29-34.
32. Matney T.S., Nguyen T.V., Connor T.H., Dana W.J., Theiss J.C. Genotoxic classification of anticancer drugs. Teratog. Carcinog. Mutagen. 5:1985;319-328.
33. Natarajan A.T., Darroudi F., Mullenders L.H., Meijers F. The nature and repair of DNA lesions that lead to chromosomal aberrations induced by ionizing radiations. Mutat. Res. 160:1986;231-236.
34. Nichols C.R., Breeden E.S., Loehrer P.J., Williams S.D., Einhorn L.H. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J. Natl. Cancer Inst. 85:1993;36-40.
35. Obe G., Natarajan A.T., Palitti F. Role of double-strand breaks in the formation of radiation-induced chromosomal aberrations. Mutat. Res. 4:1982b;1-9.
36. Pedersen-Bjergaard J., Rowley J.D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood. 83:1994;2780-2786.
37. Pommier Y., Zwelling L.A., Kao-Shan C.-S., Whang-Peng J., Bradley M.O. Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, Mutations, and cytotoxicity in Chinese hamster cells. Cancer Res. 45:1985;3143-3149.
38. Puck T.T., Marcus P.I. A rapid method for viable cell titration and clone production with HeLa cells in tissue culture The use of X-irradiated cells to supply conditioning factors. Proc. Natl. Acad. Sci. 41:1955;432-437.
39. Roy C., Brown D.L., Little J.E. et al. The topoisomerase II inhibitor teniposide (VM-26) induces apoptosis in unstimulated mature murine lymphocytes. Exp. Cell. Res. 200:1992;416-424.
40. Singh B., Gupta R.S. Mutagenic responses of thirteen anticancer drugs on mutat induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells. Cancer Res. 43(2):1983;577-584.
41. Streffer, C., van Beuningen, D., Molls, 1982. Possibilities of micronucleus test as an assay in radiotherapy. In: Krächer, K.H., Kogelnik, H.D., Reinartz, G. (Eds.), Progress in Radio Oncology II. Raven Press, New York, pp 243-251.
42. Tepper C.G., Studzinski G.P. Resistance of mitochondrial DNA to degradation characterizes the apoptotic but not the necrotic mode of human leukemia cell death. J. Cell Biochem. 52:1993;352-361.
43. Tewey K.M., Rowe T.C., Yang L., Halligan B.C., Liu L.F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 226:1984;466-468.
44. Uemura T., Yanagida M. Mitotic spindle pulls but fails to separate chromosomes in type II topoisomerase mutants: uncoordinated mitosis. EMBO J. 5:1986;1003-1010.
45. Uemura, T., Ohkra, H., Adachi, Y., Morino, K., Yanagida M., 1987. DNA topolsomerase II is required for condensation and seperation of mitotic chromosomes in S. pombe. Cell 50, 917-925.
46. van der Gaast A., Splinter T.A. Teniposide (VM-26) in ovarian cancer: a review. Semin. Oncol. 19(2 Suppl. 6):1992;95-97.
47. Vig B.K. Genetic toxicology of mitomycin C, actinomycins, daunomycin and adriamycin. Mutat. Res. 39:1977;189-238.
48. Yanagida M., Sternglanz R. Genetics of DNA topoisomerases. Cozzarelli N.R., Wang J.C. DNA Topoisomerases and its Biological Effects. 1990;299-320 Cold Spring Harbor, New York.
49. Zeimet A.G., Thaler J., Abfalter E., Marth C., Dapunt O. Secondary leukemias after etoposide. Lancet. 340:1992;379-380.
50. Zwelling L.A. Topoisomerase II as a target of antileukemia drugs: a review of controversial areas. Hematol. Pathol. 3:1989;101-112.